FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1824996723> ?p ?o ?g. }

• W1824996723 endingPage "441" @default.
• W1824996723 startingPage "431" @default.
• W1824996723 abstract "Background. Darexaban (YM150) is a potent direct factor Xa (FXa) inhibitor developed for the prophylaxis of venous and arterial thromboembolic disease. This drug is rapidly and extensively metabolized to darexaban glucuronide (YM-222714), which is a pharmacologically active metabolite. The objective of the present study was to evaluate the clinical pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of ascending multiple oral doses of darexaban in healthy non-elderly Caucasian and Japanese subjects. Methods. A randomized, double-blind, placebo-controlled, single and multiple dose-escalating study of healthy Caucasian and Japanese male and female subjects was performed. The tested doses were 20, 60, 120 and 240 mg of darexaban. Results. Plasma concentrations of darexaban glucuronide increased with dose, and Cmax and AUC increased dose-dependently after both single and repeated doses in both Caucasians and Japanese. Cmax was about 17%–19% lower in Caucasians than in Japanese, although AUC appeared to be similar. The time-profiles of prothrombin time reported as the international normalized ratio (PT-INR), activated partial thromboplastin time (aPTT) and FXa activity closely followed the time–concentration profile of darexaban glucuronide, and no clear differences were observed in ethnicity. Overall, 38 of the 82 enrolled subjects reported a total of 57 treatment-emergent adverse events (TEAEs). Fifty-five TEAEs were of mild intensity and two were of moderate intensity. Conclusion. It is concluded that single and multiple doses of darexaban are safe and well tolerated up to 240 mg with predictable PK and PD profiles in both Caucasians and Japanese, and that ethnicity does not affect its PK, PD or tolerability. Copyright © 2013 John Wiley & Sons, Ltd." @default.
• W1824996723 created "2016-06-24" @default.
• W1824996723 creator A5003428197 @default.
• W1824996723 creator A5008722654 @default.
• W1824996723 creator A5011984391 @default.
• W1824996723 creator A5039713170 @default.
• W1824996723 creator A5054529587 @default.
• W1824996723 creator A5064923299 @default.
• W1824996723 creator A5081633655 @default.
• W1824996723 creator A5085070792 @default.
• W1824996723 date "2013-09-20" @default.
• W1824996723 modified "2023-10-17" @default.
• W1824996723 title "Clinical pharmacokinetics, pharmacodynamics, safety and tolerability of darexaban, an oral direct factor Xa inhibitor, in healthy Caucasian and Japanese subjects" @default.
• W1824996723 cites W1494668822 @default.
• W1824996723 cites W1631441099 @default.
• W1824996723 cites W1968259952 @default.
• W1824996723 cites W1977418630 @default.
• W1824996723 cites W1980536507 @default.
• W1824996723 cites W1980812741 @default.
• W1824996723 cites W1983967306 @default.
• W1824996723 cites W1986131884 @default.
• W1824996723 cites W1999468381 @default.
• W1824996723 cites W2022289628 @default.
• W1824996723 cites W2022932023 @default.
• W1824996723 cites W2055457865 @default.
• W1824996723 cites W2066736865 @default.
• W1824996723 cites W2076983947 @default.
• W1824996723 cites W2096698984 @default.
• W1824996723 cites W2120064023 @default.
• W1824996723 cites W2159370562 @default.
• W1824996723 cites W2170104411 @default.
• W1824996723 cites W2587914042 @default.
• W1824996723 doi "https://doi.org/10.1002/bdd.1858" @default.
• W1824996723 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23929659" @default.
• W1824996723 hasPublicationYear "2013" @default.
• W1824996723 type Work @default.
• W1824996723 sameAs 1824996723 @default.
• W1824996723 citedByCount "12" @default.
• W1824996723 countsByYear W18249967232015 @default.
• W1824996723 countsByYear W18249967232016 @default.
• W1824996723 countsByYear W18249967232017 @default.
• W1824996723 countsByYear W18249967232020 @default.
• W1824996723 countsByYear W18249967232022 @default.
• W1824996723 countsByYear W18249967232023 @default.
• W1824996723 crossrefType "journal-article" @default.
• W1824996723 hasAuthorship W1824996723A5003428197 @default.
• W1824996723 hasAuthorship W1824996723A5008722654 @default.
• W1824996723 hasAuthorship W1824996723A5011984391 @default.
• W1824996723 hasAuthorship W1824996723A5039713170 @default.
• W1824996723 hasAuthorship W1824996723A5054529587 @default.
• W1824996723 hasAuthorship W1824996723A5064923299 @default.
• W1824996723 hasAuthorship W1824996723A5081633655 @default.
• W1824996723 hasAuthorship W1824996723A5085070792 @default.
• W1824996723 hasConcept C111113717 @default.
• W1824996723 hasConcept C112705442 @default.
• W1824996723 hasConcept C126322002 @default.
• W1824996723 hasConcept C142724271 @default.
• W1824996723 hasConcept C149151106 @default.
• W1824996723 hasConcept C197934379 @default.
• W1824996723 hasConcept C204787440 @default.
• W1824996723 hasConcept C22979827 @default.
• W1824996723 hasConcept C27081682 @default.
• W1824996723 hasConcept C2777288759 @default.
• W1824996723 hasConcept C2778261982 @default.
• W1824996723 hasConcept C2778375690 @default.
• W1824996723 hasConcept C2780434524 @default.
• W1824996723 hasConcept C71924100 @default.
• W1824996723 hasConcept C89560881 @default.
• W1824996723 hasConcept C90924648 @default.
• W1824996723 hasConcept C98274493 @default.
• W1824996723 hasConceptScore W1824996723C111113717 @default.
• W1824996723 hasConceptScore W1824996723C112705442 @default.
• W1824996723 hasConceptScore W1824996723C126322002 @default.
• W1824996723 hasConceptScore W1824996723C142724271 @default.
• W1824996723 hasConceptScore W1824996723C149151106 @default.
• W1824996723 hasConceptScore W1824996723C197934379 @default.
• W1824996723 hasConceptScore W1824996723C204787440 @default.
• W1824996723 hasConceptScore W1824996723C22979827 @default.
• W1824996723 hasConceptScore W1824996723C27081682 @default.
• W1824996723 hasConceptScore W1824996723C2777288759 @default.
• W1824996723 hasConceptScore W1824996723C2778261982 @default.
• W1824996723 hasConceptScore W1824996723C2778375690 @default.
• W1824996723 hasConceptScore W1824996723C2780434524 @default.
• W1824996723 hasConceptScore W1824996723C71924100 @default.
• W1824996723 hasConceptScore W1824996723C89560881 @default.
• W1824996723 hasConceptScore W1824996723C90924648 @default.
• W1824996723 hasConceptScore W1824996723C98274493 @default.
• W1824996723 hasIssue "8" @default.
• W1824996723 hasLocation W18249967231 @default.
• W1824996723 hasLocation W18249967232 @default.
• W1824996723 hasOpenAccess W1824996723 @default.
• W1824996723 hasPrimaryLocation W18249967231 @default.
• W1824996723 hasRelatedWork W1857288271 @default.
• W1824996723 hasRelatedWork W1972266366 @default.
• W1824996723 hasRelatedWork W2029341269 @default.
• W1824996723 hasRelatedWork W2035952571 @default.
• W1824996723 hasRelatedWork W2110223924 @default.
• W1824996723 hasRelatedWork W2128846056 @default.

• next